D-Tagatose is a low-calorie sugar substitute that has gained increased attention as a functional sweetener owing to its nutraceutical and prebiotic properties. Traditionally, D-tagatose is produced via the enzymatic conversion of L-galactose to D-tagatose by L-arabinose isomerase (L-AI). Nonetheless, the most reported L-AI enzymes are ion-dependent enzymes requiring Mn2+ and/or Co2+ as cofactors for their reactions, which limits their application due to safety and health concerns. Herein, we addressed the facile bioconversion of L-galactose to D-tagatose using a novel recombinant metallic-ions-independent L-AI derived from endophytic Bacillus amyloliquefaciens CAAI isolated from cantaloupe fruits. The ORF (1500 bp) of the L-arabinose isomerase gene (araA) was cloned and over-expressed in Escherichia coli. The recombinant enzyme (BAAI) was purified to homogeneity using Ni-NTA affinity chromatography, yielding a single distinct band with an apparent molecular mass of approximately 59 kDa as deduced from SDS-PAGE analysis. The purified enzyme showed optimum activity at pH and temperature of 7.5 and 45 °C, respectively, with obvious enzymatic activity in the presence of ethylenediaminetetraacetic acid (EDTA), indicating the metallic-ions independence from BAAI. The Km values of BAAI for D-galactose and L-arabinose were 251.6 mM and 92.8 mM, respectively. The catalytic efficiency (kcat/Km) values for D-galactose and L-arabinose were found to be 2.34 and 46.85 mM–1 min–1, respectively. The results revealed the production of 47.2 g/L D-tagatose from D-galactose (100 g/L) with 47.2% bioconversion efficiency in a metallic-ions-free reaction system that could be implemented in safe-production of food-grade low-calorie sweetener, D-tagatose.
Background: Understanding COVID-19’s onset and clinical effects requires knowing host immune responses. Objective: To investigate the presence of IgM, IgG, and cytokine levels (IL-2 and IL-6) in individuals with COVID-19 who have had their diagnosis confirmed by PCR. Methods: This cross-sectional research included 70 adult ICU patients from King Abdullah Hospital in Bisha, Saudi Arabia. Subjects gave two blood samples. After hospital release, only 21 patients provided the second sample. Each patient provided a sample upon admission. Quantitative ELISAs evaluated IL-2, IL-6, and SARS-CoV-2-specific IgM and IgG antibodies. Results: All patients were critically ill and unvaccinated against COVID-19. 46 (65.7%) of the patients were male, and their age range was 33– 98 years (with a mean age of 66.5); 24.3%) were 51– 61 years old. IgG was positive in all patients, although IgM predominated in 57/70 (81.4%) (6– 1200 IU/mL). Total data analysis yielded these results. IL-6 was calculated at 10– 1900 ng/mL, whereas IL-2 was 4– 280. Discharged hospital patients had a statistically significant increase in IgM and IgG (P = 0.01, 0.004) but a statistically insignificant decline in IL-6 and IL-2 (P = 0.761, 0.071). Low IgM levels increased hospital stays. The study found lengthier hospital stays with higher IgG levels. Conclusion: The identification of IgM and IgG antibodies, greater IL-6 levels, and lower IL-2 levels can help diagnose and monitor COVID-19 infection.
Background: Pregnancies are usually associated with increase tendency to thrombosis; many cases are associated with inherited or acquired risks. Objective: The present study tested the mutations in Factor V Leiden (FVL) G1691A, prothrombin (PT) G20210A, methylene-tetrahydrofolate reductase (MTHFR) C677T genes, and their association with recurrent pregnancy losses in Egyptian women. Results: The study included 150 subjects of a history of one or more recurrent pregnancy losses matched with 100 normal subjects with a history of normal delivery with no complications. FVL G1691A mutation was detected in (38%) of patients and in (5%) of control. PT G20210A mutation was detected in (6%) of patients with no detection in control. MTHFR C677T mutation was detected in (45.4%) of patients and in (4%) of control. Homozygous with mutant alleles for the three studied mutations were detected only among patients not control group. Conclusion: There is a significant association between mutations of FVL, PT and MTHFR and recurrent pregnancy loss in Egyptian women.
1 January 2025 in Arquivo Brasileiro de Medicina Veterinária e Zootecnia
Milk samples enriched in conjugated linoleic acid (CLA) were obtained from buffalos fed on special diet supplemented with olive oil and sunflower oil mixture (1:1) with monensin oil to enhance the production of CLA. The effect of CLA rich milk on cancer growth was studied both in vitro and in vivo. For the in vitro study, the viability of 3 cancer cell lines, HeLa, HepG-2, and MCF-7, and the viability was examined by neutral red assay following the culture with special media containing CLA rich milk. For the in vivo study, ninety female mature mice were used in two experiments, 45 mice in each experiment, to investigate the effect of feeding milk rich in CLA on life span and the survival rate of mice transplanted with Ehrlich Ascites Carcinoma cells (EACC). Results of the in vitro study showed that both normal milk as well as milk rich in CLA enhanced cell survival of the cancer cell lines. However, the viability of these cells was significantly reduced (80%) when lipid fractions of milk samples were used instead of whole milk. This effect may be due to the essential fatty acid component of CLA rich milk which enhanced the inhibition of cancer cells’ growth. Our results were confirmed when the viability of cancer cells was significantly decreased when CLA was added to their incubation media. Data from the in vivo study showed that the life span of tumor transplanted mice fed milk rich in CLA was longer than that of mice transplanted fed either a normal diet or fed normal milk diets. We concluded that milk rich in CLA has clear anticancer activity in vitro and in vivo. Our results reveal that the action is due to the unsaturated fatty acids, especially CLA which may enhance cancer cells to enter apoptosis.
Sepsis is characterized by multiple organ dysfunction, which is now accepted to be due to oxidative damage. The lung is the first organ exposed to this damage, and its injury is one of the leading causes of death. Therefore, many pharmacological strategies are employed to attenuate sepsis. This study aimed to evaluate the in silico and in vitro antibacterial activity of Cicer arietinum extract (CAE) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa and the in vivo modulatory effect of CAE against sepsis induced by cecal ligation and puncture (CLP) in rats. This study identified seven bioactive components in Cicer arietinum extract, revealing promising interactions between these components and Staphylococcus aureus-PBP2a and Pseudomonas aeruginosa-PBP3 proteins, highlighting their potential as novel antibacterial agents. After ensuring the bactericidal ability of CAE against Staphylococcus aureus and Pseudomonas aeruginosa, an in vivo study was performed. Twenty-four rats were divided into sham-operated rats, CLP-septic rats, CLP rats treated with CAE (500 mg/kg b.wt), and CLP rats treated with hydrocortisone (25 mg/ kg b.wt). CAE was administered orally for 3 days post-operation, and animals were euthanized on the fourth day. Another twenty-four rats were used to study survival for 5 days. This study revealed that CAE, like hydrocortisone, can rescue CLP rats from death by suppressing lung procalcitonin (PCT) and MDA and enhancing SOD, CAT, and GSH levels significantly, as compared with the CLP group. The histopathological results were parallel with the biochemical results since the CLP rats treated with CAE had lower histological/inflammatory scores in the lung like hydrocortisone. The beneficial role of CAE may result from its antibacterial and antioxidant activities, and CAE can be considered as a lung antiseptic extract. This study provides a novel treatment for sepsis-induced ALI. However, the beneficial impact of CAE needs extensive study to obtain evidence.